Department of Radiation Oncology, Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia; University of Queensland, Brisbane, Queensland, Australia.
Disease Center Leader, Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Lancet Oncol. 2017 May;18(5):e274-e283. doi: 10.1016/S1470-2045(17)30229-2. Epub 2017 Apr 26.
Head and neck cancer in elderly patients represents a major health burden because its management provides unique and complex challenges for multidisciplinary teams, such as reduced treatment tolerance, multiple comorbidities, and altered pharmacokinetics and pharmacodynamics. Despite the prominent challenges involved, high-level evidence for the management of this group of patients is scarce. Substantial advances in treatment, such as robotic surgery, dynamic intensity-modulated radiation therapy, immunotherapy, and de-escalation trials, might allow for improved treatment tolerance in this patient population. Advanced age alone does not appear to be a contraindication to curative treatment. Evaluation of age-specific factors such as life expectancy, impaired functional status, and cognitive decline warrant consideration as part of the management decision process. In this Review, we provide an update of the available evidence on the management of locoregionally confined head and neck cancer in elderly patients and propose a practical treatment algorithm for clinicians to help manage this patient population.
老年头颈部癌症患者是一个主要的健康负担,因为其治疗给多学科团队带来了独特而复杂的挑战,如治疗耐受性降低、多种合并症、药代动力学和药效学改变。尽管存在这些突出的挑战,但针对这群患者的高级别证据仍然很少。治疗方面的重大进展,如机器人手术、动态强度调制放疗、免疫疗法和降级试验,可能会提高这一患者群体的治疗耐受性。单纯年龄增长本身似乎并不是根治性治疗的禁忌症。评估预期寿命、功能状态受损和认知能力下降等特定于年龄的因素,作为管理决策过程的一部分,值得考虑。在这篇综述中,我们提供了有关局部晚期老年头颈部癌症治疗的现有证据的最新信息,并为临床医生提出了一个实用的治疗方案,以帮助管理这一患者群体。